Back to top
more

Nektar Therapeutics (NKTR)

(Real Time Quote from BATS)

$1.69 USD

1.69
183,541

-0.01 (-0.59%)

Updated May 22, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock

Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, combined with the other party's Opdivo and Opdivo plus Yervoy.

    Nektar (NKTR) Surges: Stock Moves 11% Higher

    Nektar (NKTR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

      Sweta Killa headshot

      5 Best-Performing Stocks of the Top ETF of January

      Inside the top performing stocks of the top biotech ETF of January.

        Here's Why Nektar Stock Skyrocketed Almost 500% in a Year

        Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.

          Nektar Boasts Strong Pipeline, Competition Remains a Woe

          Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

            Why is Nektar (NKTR) Stock Up More Than 350% This Year?

            Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.

              Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions?

              Nektar Therapeutics (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?

                Investors in Nektar (NKTR) need to pay close attention to the stock based on moves in the options market lately.

                  Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

                  Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.

                    Company News For Nov 14, 2017

                    Companies in the news are: TSN,JD,NKTR,GGP

                      Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II

                      Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.

                        Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up

                        Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.

                          Nektar Therapeutics (NKTR) Jumps: Stock Rises 10.54%

                          Nektar Therapeutics (NKTR) was a big mover last session, as the company saw its shares nearly 11% on the day amid huge volumes.

                            Implied Volatility Surging for Nektar (NKTR) Stock Options

                            Nektar (NKTR) needs investors to pay close attention to the stock based on moves in the options market lately.

                              Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe

                              Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

                                Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate

                                Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.

                                  Surging Earnings Estimates Signal Good News for Nektar (NKTR)

                                  Nektar (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                                    Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock?

                                    Investors Nektar (NKTR) need to pay close attention to the stock based on moves in the options market lately.

                                      Will Nektar's (NKTR) Candidates Enhance Growth in 2017?

                                      Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

                                        Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag

                                        Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.

                                          Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock?

                                          Investors in Nektar Therapeutics (NKTR) need to pay close attention to the stock based on moves in the options market lately.

                                            Nektar's NKTR-181 Positive in Human Abuse Potential Study

                                            Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.

                                              Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options

                                              Nektar Therapeutics (NKTR) needs Investors to pay close attention to the stock based on moves in the options market lately.

                                                5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017

                                                London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.

                                                  Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

                                                  Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.